Travere Therapeutics, Inc. (TVTX)
52.12
+0.08
(+0.16%)
USD |
NASDAQ |
Oct 09, 16:00
52.17
+0.04
(+0.09%)
After-Hours: 20:00
Travere Therapeutics Enterprise Value : 5.037B for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 5.037B |
| October 08, 2026 | 5.029B |
| October 07, 2026 | 5.160B |
| October 06, 2026 | 5.400B |
| October 05, 2026 | 5.559B |
| October 02, 2026 | 5.489B |
| October 01, 2026 | 5.482B |
| September 30, 2026 | 5.673B |
| September 29, 2026 | 5.777B |
| September 28, 2026 | 5.926B |
| September 25, 2026 | 5.725B |
| September 24, 2026 | 5.837B |
| September 23, 2026 | 5.762B |
| September 22, 2026 | 5.805B |
| September 21, 2026 | 6.048B |
| September 18, 2026 | 6.038B |
| September 17, 2026 | 6.225B |
| September 16, 2026 | 6.106B |
| September 15, 2026 | 6.015B |
| September 14, 2026 | 6.323B |
| September 11, 2026 | 6.359B |
| September 10, 2026 | 6.485B |
| September 09, 2026 | 6.364B |
| September 08, 2026 | 6.350B |
| September 04, 2026 | 6.275B |
| Date | Value |
|---|---|
| September 03, 2026 | 6.394B |
| September 02, 2026 | 6.459B |
| September 01, 2026 | 6.316B |
| August 31, 2026 | 6.370B |
| August 28, 2026 | 6.312B |
| August 27, 2026 | 6.486B |
| August 26, 2026 | 6.449B |
| August 25, 2026 | 6.438B |
| August 24, 2026 | 6.270B |
| August 21, 2026 | 6.316B |
| August 20, 2026 | 6.198B |
| August 19, 2026 | 6.339B |
| August 18, 2026 | 6.145B |
| August 17, 2026 | 6.111B |
| August 14, 2026 | 5.980B |
| August 13, 2026 | 5.913B |
| August 12, 2026 | 5.982B |
| August 11, 2026 | 5.798B |
| August 10, 2026 | 5.862B |
| August 07, 2026 | 5.903B |
| August 06, 2026 | 6.009B |
| August 05, 2026 | 6.038B |
| August 04, 2026 | 5.403B |
| August 03, 2026 | 5.305B |
| July 31, 2026 | 5.391B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| TG Therapeutics, Inc. | 8.678B |
| BioMarin Pharmaceutical, Inc. | 13.95B |
| Vertex Pharmaceuticals, Inc. | 123.34B |
| Viridian Therapeutics, Inc. | 1.472B |
| Krystal Biotech, Inc. | 8.978B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.80M |
| Revenue (Quarterly) | 169.58M |
| Total Expenses (Quarterly) | 204.38M |
| EPS Diluted (Quarterly) | -0.3722 |
| Gross Profit Margin (Quarterly) | 96.22% |
| Profit Margin (Quarterly) | -20.52% |
| Earnings Yield | -1.46% |
| Normalized Earnings Yield | -0.8904 |